The Brent Saun­ders way: Al­ler­gan pays $95M for its next step­ping stone to a big­ger pipeline

Al­ler­gan has picked up an­oth­er one of its “step­ping stone” ac­qui­si­tions. The deal-hun­gry com­pa­ny bagged For­Sight VI­SION5 and its glau­co­ma tech­nol­o­gy for a $95 mil­lion up­front and an un­spec­i­fied launch mile­stone.

In re­turn for its mon­ey Al­ler­gan gets a new tech – a preser­v­a­tive-free bi­mato­prost oc­u­lar in­sert – that has passed its Phase II chal­lenge in prov­ing its abil­i­ty to re­li­ably low­er in­traoc­u­lar pres­sure for a pe­ri­od of time. It’s be­ing set up as a ther­a­py for pa­tients who have a hard time with eye drop reme­dies. And Al­ler­gan will be buy­ing the Men­lo Park, CA-based biotech as it sits on the thresh­old of Phase III – which is its sweet spot in R&D.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER